Phase Ib study of PTC299, a novel oral inhibitor of tumor VEGF expression, in patients with advanced cancer.

3041 Background: PTC299 is a novel, oral investigational drug designed to inhibit tumor expression of VEGF and other angiogenic cytokines. PTC299–administered alone or in combination with taxanes–h...